Chye-Gen Chin, Yu-Cheng Hsieh, Wei-Shiang Lin, Yenn-Jiang Lin, Chuen-Wang Chiou, Tsung-Hsien Lin, Chien-Lung Huang, Yuan Hung, Yung-Kuo Lin, Shih-Lin Chang, Tong-Chen Yeh, Hsiang-Chun Lee, Wen-Ter Lai, Ming-Hsiung Hsieh
BACKGROUND: Propafenone is a class IC antiarrhythmic agent that is commonly used as the first-line therapy for patients with paroxysmal atrial fibrillation (AF) in Taiwan. This study compared the efficacy and safety of generic (Rhynorm) and brand name (Rytmonorm) propafenone for rhythm control of paroxysmal AF in Taiwan. METHODS: This was an open-label randomized multicenter noninferior study conducted in Taiwan. We enrolled 76 patients with AF. To investigate the efficacy of propafenone, we used a wearable ECG event recorder to evaluate the daily burden of AF episodes in patients for 24 weeks...
February 17, 2023: Journal of the Chinese Medical Association: JCMA